An expert in pediatric rheumatology, Karen Onel, MD, cares for children and teens with arthritis and other autoimmune disorders. In particular, she diagnoses and treats: lupus, juvenile arthritis, vasculitis, uveitis (an inflammatory disorder of the eye), chronic non-infectious osteomyelitis, dermatomyositis and the periodic fever syndromes. Her goal is to work with the patient and his/her family to create a long-term care plan that will lead to improved quality of life.
Dr. Onel's research focuses on gaining a greater understanding of the causes of rheumatic illnesses, as well as evaluating the safety and tolerability of new treatments. She is collaborating with other institutions to define evidence-based best treatment practices for children with JIA, SLE and recurrent non-infectious osteomyelitis.
Dr. Onel has authored numerous papers, reviews and book chapters on pediatric rheumatology. In addition, she serves as a reviewer for many scientific journals, is on the editorial board of Pediatric Rheumatology and is Associate Editor for Seminars in Arthritis and Rheumatism.
Please call our office if you have questions regarding your insurance coverage. If you have out of network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Chief, Pediatric Rheumatology, Hospital for Special Surgery
Attending Physician, Hospital for Special Surgery
Castle Connolly America's Top Doctors, 2014-2021
Castle Connolly Top Doctors in New York Metro Area, 2018-2022
New York Magazine Top Doctors, 2018-2022
Chicago Magazine Top Doctors, 2012, 2014, 2016
Amgen Pediatric Rheumatology Visiting Professorship, 2014, 2015
Chicago Arthritis Walk Medical Honoree, 2013
ACR Pediatric Rheumatology Research Award, 1994
Fellowship ACR Senior Rheumatology Scholar Award, 1994
Mitchell Spivak Memorial Prize in Pediatrics, 1989
Janet M. Glasgow Memorial Achievement Citation, 1989
Alpha Omega Alpha, 1988
Cornell University Medical College, New York
Columbia Presbyterian Medical Center, New York
Columbia Presbyterian Medical Center, New York
Hospital for Special Surgery, New York
Brunner HI, Bennett M, Abulaban K, Klein-Gitelman M, O'Neil K, Tucker L, Ardoin S, Rouster-Stevens K, Onel KB, Singer N, Eberhard BA, Jung L, Imundo L, Wright T, Witte D, Rovin B, Ying J, and Devarajan P. Development of a novel renal activity index of lupus nephritis in children & young adults. Arthritis Care Res (Hoboken). July; 68(7):1003-1011, 2016
Knight A, Vickery M, Muscal E, Davis A, Harris JG, Soybilgic A, Onel K, Schanberg LE, Rubinstein T, Gottlieb BS, Mandell DS, and von Scheven E. Identifying Targets for Improving Mental Health Care of Adolescents with Lupus: Perspectives from Pediatric Rheumatology Clinicians in the United States and Canada
J Rheumatol. Jun;43(6):1136-45, 2016
Mina R, Abulaban K, Klein-Gitelman M, Eberhard A, Ardoin S, Singer N, Onel KB, Tucker L, O'Neil K, Wright T, Brooks E, Rouster-Stevens K, Jung L, Imundo L, Rovin B, Witte D, Ying J, and Brunner HI. Validation of the lupus nephritis clinical indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res. Feb;68(2):195-202, 2016
Ringold S, Hendrickson A, Abramson L, Beukelman T, Blier PR, Bohnsack J, Chalom EC, Gewanter HL, Gottlieb B, Hollister R, Hsu J, Hudgins A, Ilowite NT, Klein-Gitelman M, Lindsley C, LopezBenitez JM, Lovell DJ, Mason T, Milojevic D, Moorthy LN, Nanda K, Onel KB et al. A novel method to collect medication adverse events in juvenile arthritis: Results from the Childhood Arthritis and rheumatology research alliance enhanced drug safety surveillance project (EDSSP). Arthritis Care Res. Apr; 67(4):529-37, 2015.
Mina R, Klein-Gitelman MS, Nelson S, Eberhard BA, Higgins G, Singer NG, Onel KB, Tucker L, O'Neil KM, Punaro M, Levy DM, Haines K, Ying J, and Brunner HI. Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus. Lupus. Feb;24(2):191-7, 2015.
Sobel, RE, Lovell DJ, Brunner HI, Weiss JE, Morris PW, Gottlieb BS, Chalom EC, Jung LK, Onel KB, Petiniot L, Goldsmith DP, Nanda K, Shishov M, Abramsky S, Young JP, and Giannini EH. Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry. Pediatr Rheumatol. 12:29. 2014.
Soybilgic A, Tesher M, Wagner-Weiner L, and Onel KB. A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America. Pediatr Rheumatol. 12:24. 2014.
Ringold S, Weiss PF, Colbert RA, Dewitt EM, Lee T, Onel KB, Prahalad S, Schneider R, Shenoi S, Vehe RK, and Kimura Y. Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res. Jul;66(7):1063-72, 2014.
Mina R, Klein-Gitelman MS, Nelson S, Eberhard BA, Higgins G, Singer NG, Onel KB, Tucker L, O'Neil KM, Punaro M, Levy DM, Haines K, Martini A, Ruperto N, Lovell D, and Brunner, HI. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Ann Rheum Dis. Feb 73(2):401-6, 2014.
Soybilgic, A, Onel KB, Utset T, Alexander K, and Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J. Aug 7;11:29 2013.
Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, Wallace CA, Onel KB, Foell D, Wu R, Biedermann S, Hamilton JD, and Radin AR. Long-Term Safety and Efficacy of Rilonacept in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA). Arthritis Rheum. Sep;65:2486-96, 2013.
For more publications, please see the PubMed listing.
JIA in the 21st Century.” Pediatric Grand Rounds, NYP Brooklyn Methodist Hospital, 2019
Challenges in Juvenile Arthritis. Pediatric Rheumatology: An Update for Clinicians, NYU, New York, March, 13 2019
When aches and pains are more than aches and pains. NYC Department of Health and Mental Health, Office of School Health Physicians, New York, NY, December 18, 2019
2020 ACR Guideline for the Treatment of JIA:
Therapeutic Approaches for Oligoarthritis, TMJ Arthritis, and Systemic JIA, Medication Monitoring, Immunizations and Non-Pharmacologic Therapies.” ACR Convergence, Annual Scientific Meeting of the American College of Rheumatology.” Atlanta, Ga.. November, 2020
Therapeutic Approaches for Oligoarthritis, TMJ Arthritis, and SystemicJIA,Medication Monitoring, Immunizations and Non-Pharmacologic Therapies.” The best of ACR Convergence. Riyadh, Saudi Arabia, 2020
Therapeutic Approaches for Oligoarthritis, TMJ Arthritis, and SystemicJIA,Medication Monitoring, Immunizations and Non-Pharmacologic Therapies.” The best of ACR Convergence. Beijing, China, 2021
How much conflict is too much. Pediatric Grand Rounds, Rheumatology Grand Rounds Hospital for Special Surgery, January, 2021
How much conflict is too much. Pediatric Grand Rounds, University of Chicago Medicine, Chicago, IL, 2021
Systemic JIA. Pediatric Rheumatology Grand Rounds, Riley Children’s Hospital, Indianapolis, IN, 2021
Covid in childhood. State of the Art, American College of Rheumatology, April 11, 2021
How I learned to love this topic (COI). Pediatric Professors Rounds, Weill Cornell Pediatrics New York, July 9, 2021
Ethics of biobanking & genetic research in Pediatric Rheumatology. ACR Convergence Annual Scientific Meeting of the American College of Rheumatology. San Francisco, Ca, November 7, 2021
Current interests include:
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Onel as of September 20, 2019.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.